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Summary
Background The link between adiposity, metabolic abnormalities, and arterial disease progression in children and 
adolescents remains poorly defined. We aimed to assess whether persistent high adiposity levels are associated with 
increased arterial stiffness in adolescence and any mediation effects by common metabolic risk factors.
Methods We included participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) who had 
detailed adiposity measurements between the ages 9–17 years and arterial stiffness (carotid to femoral pulse wave 
velocity [PWV]) measured at age 17 years. Body-mass index (BMI) and waist-to-height ratio were calculated from 
weight, height, and waist circumference measurements whereas fat mass was assessed using repeated dual-energy 
x-ray absorptiometry (DEXA) scans. We used total and trunk fat mass indices (FMIs) to classify participants as normal 
(<75th percentile) or high (>75th percentile) FMI. We classified participants as being metabolically unhealthy if they 
had three or more of the following risk factors: high levels of systolic blood pressure, triglycerides, or glucose (all 
>75th percentile) or low levels of high-density lipoprotein (<25th percentile). We used multivariable linear regression 
analysis to assess the relationship between PWV and exposure to adiposity, and tested for linear trend of PVW levels 
across ordinal groups. We used latent class growth mixture modelling analysis to assess the effect of longitudinal 
changes in adiposity indices through adolescence on arterial stiffness.
Findings We studied 3423 participants (1866 [54·5%] female and 1557 [45·5%] male). Total fat mass was positively 
associated with PWV at age 17 years (0·004 m/s per kg, 95% CI 0·001–0·006; p=0·0081). Persistently high total FMI 
and trunk FMI between ages 9 and 17 years were related to greater PWV (0·15 m/s per kg/m², 0·05–0·24; p=0·0044 
and 0·15 m/s per kg/m², 0·06–0·25; p=0·0021) compared with lower FMI. Metabolic abnormalities amplified the 
adverse effect of high total FMI on arterial stiffness (PWV 6·0 m/s [95% CI 5·9–6·0] for metabolically healthy 
participants and 6·2 m/s [5·9–6·4] for metabolically unhealthy participants). Participants who restored normal total 
FMI in adolescence (PWV 5·8 m/s [5·7–5·9] for metabolically healthy and 5·9 m/s [5·6–6·1] for metabolically 
unhealthy) had comparable PWV to those who had normal FMI throughout (5·7 m/s [5·7–5·8] for metabolically 
healthy and 5·9 m/s [5·8–5·9] for metabolically unhealthy).
Interpretation Persistently high fat mass during adolescence was associated with greater arterial stiffness and was 
further aggravated by an unfavourable metabolic profile. Reverting to normal FMI in adolescence was associated with 
normal PWV, suggesting adolescence as an important period for interventions to tackle obesity in the young to 
maximise long-term vascular health.
Funding UK Medical Research Council, Wellcome Trust, British Heart Foundation, and AFA Insurances
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Introduction
Over the past four decades, there has been an alarming 
increase in the prevalence and incidence of obesity in 
both developed and developing countries,1 with the 
fastest rises in adiposity levels reported in children, 
adolescents, and young adults. This increase at younger 
ages represents a growing threat to worldwide public 
health because obesity in childhood tracks to adulthood 
and is associated with a disturbed cardiometabolic profile 
and accelerated progression of atherosclerotic disease in 
adulthood.2–4 Although the association between adiposity 
and cardiovascular disease in adults is well described, the 
link between adiposity and arterial disease progression 
in children and adolescents remains unclear.
Our group has previously shown that children with 
adiposity had a higher heart rate, greater resting and 
reactive hyperaemic blood flow, and larger arterial 
diameters compared with children with normal weight.5–8 
Children with adiposity had a greater endothelial 
function and less arterial stiffness than did children of a 
normal weight, suggesting an adaptive hyperaemic state 
in response to pre-pubertal adiposity. However, whether 
similar adaptive responses, which are not necessarily 
unhealthy at this stage, persist in adolescence remains to 
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be established. Because of rapid changes in body 
composition during adolescence, direct and repeated 
measurements of fat are needed to decipher the 
independent effect of growth from that of adiposity on 
vascular health.
In the Avon Longitudinal Study of Parents and Children 
(ALSPAC), we used dual-energy x-ray absorptiometry 
(DEXA) and other proxy estimates of adiposity such as 
body-mass index (BMI) and waist-to-height ratio to 
characterise persistent adiposity from childhood to 
young adulthood and its effect on arterial stiffness at 
17 years of age. This longitudinal assessment provided us 
with the opportunity to construct trajectories of adiposity 
and to address the specific questions of whether 
persistent high adiposity levels are associated with 
increased arterial stiffness in adolescence and, if so, 
whether this effect is mediated by the presence of other 
metabolic risk factors commonly seen in individuals 
with adiposity.
Methods
Study design and participants
ALSPAC is a prospective birth cohort study investigating 
factors that influence normal childhood development 
and growth. The cohort and study design have been 
described in detail previously and are available on the 
ALSPAC website.9,10 For our analysis, we included all 
participants who had detailed adiposity measurements 
using repeated DEXA scans at ages 9 and 17 years and 
arterial stiffness measured at age 17 years. Ethical 
approval for all aspects of this study was obtained from 
the ALSPAC Ethics and Law Committee and the Local 
Research Ethics Committee and conformed to the 
Declaration of Helsinki.
Procedures
To characterise adiposity, weight, height, and waist 
circumference were measured at 2-year intervals from 
ages 9 to 17 years, from which BMI and waist-to-height 
ratio were calculated.5 Fat mass was assessed using 
DEXA at ages 9, 11, 13, 15, and 17 years. The reproducibility 
of DEXA measures in our cohort has been previously 
reported,11 and the repeatability coefficient was 0·5 kg for 
total body mass. Total and trunk fat mass indices (FMIs) 
were calculated by dividing total and trunk fat mass by 
squared height, whereas the fat-free mass index was 
generated by dividing fat-free mass by squared height. 
Participants were classified as high FMI if total sex-and 
height-adjusted FMI was greater than the 75th percentile 
of the dataset. Detailed information about the methods 
used is found in the appendix.
Vascular phenotype was determined when participants 
were 17 years old: pressure waveforms were obtained 
using the Vicorder device (Skidmore Medical, Bristol, UK) 
at carotid and femoral artery level and pulse wave velocity 
(PWV) was calculated using an inbuilt cross-correlation 
algorithm previously validated for use in adolescents.12 All 
measurements were taken independently by one of 
two trained vascular technicians (one of whom was AR; 
inter-observer mean difference 0·2 m/s, SD 0·1).
Blood pressure was recorded at ages 9 and 17 years. 
Non-fasting blood samples were taken using standard 
procedures at age 9 years, whereas overnight fasting 
samples were collected for analysis at age 17 years. 
Plasma lipids (total cholesterol, triglycerides, and high-
density lipoprotein [HDL] cholesterol) were measured by 
modification of the standard Lipid Research Clinics 
protocol using enzymatic reagents for lipid deter-
mination. All assays were considered reliable, with small 
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Research in context
Evidence before this study
Adiposity in children and adolescents represents a major 
public health challenge and a driver of both diabetes and 
cardiovascular disease in childhood and in later life. There has 
been controversy about the importance of fat phenotype and 
associated metabolic disturbances on the initiation and 
progression of early arterial disease. We searched Google Scholar 
and PubMed from inception to Dec 18, 2018, for references 
from studies on longitudinal adiposity, associated with 
measurement of vascular stiffness and metabolic health in a 
large population of children. The search terms we used included 
“longitudinal adiposity OR obesity OR DXA”, “children OR 
adolescents”, “vascular OR arterial stiffness” and “metabolic”. 
No previous studies in children or adolescents using serial 
dual-energy x-ray absorptiometry measurements for 
longitudinal assessment of adiposity throughout adolescence 
as well as measurements of metabolic health and arterial 
stiffness were found in our search.
Added value of this study
We showed that participants with persistent adiposity (measured 
as increased fat mass) between 9 and 17 years of age had worse 
arterial stiffness at age 17 years and that restoration of a normal 
fat mass was associated with arterial stiffness levels that were 
comparable to those who had normal fat mass throughout 
childhood and adolescence. The association between high fat 
mass and greater arterial stiffness was further aggravated when 
metabolic abnormalities such as dyslipidaemia and increased 
blood pressure coexisted with increased adiposity.
Implications of all the available evidence
Combined with previous findings, the results of our study have 
important implications for preventive approaches, which need to 
start in early life and have the potential to influence favourably the 
development of arterial disease. Future research needs to not only 
understand the control of fat mass development in childhood and 
adolescence, but also determine effective interventions to prevent 
and treat childhood overweight and obesity.
See Online for appendix
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coefficients of variation of less than 5%. Non-HDL 
cholesterol was calculated as total cholesterol minus 
HDL cholesterol. The amount of weekly vigorous 
physical activity was assessed by accelerometer at ages 
9 and 15 years. Further details regarding cardiovascular 
risk factor assessment can be found in the appendix.
Similarly to the modified National Cholesterol Education 
Program and International Diabetes Federation definitions 
of paediatric metabolic syndrome,13 participants were 
classified as metabolically unhealthy at either 9 or 17 years 
of age if they had three or more of the following risk factors: 
systolic blood pressure higher than the 75th percentile, 
HDL lower than the 25th percentile, triglycerides higher 
than the 75th percentile, and glucose higher than the 
75th percentile.13
Statistical analysis
All normally distributed variables are expressed as 
mean (SD). Normal distribution of parameters that 
were used as dependent variables in statistical tests was 
assessed by histograms and quantile–quantile plots. 
Partial correlations between adiposity measurements 
were assessed with Spearman’s correlation coefficient. 
Unadjusted comparisons of variables between male and 
female participants were done using linear regression, 
independent-samples Student’s t test, Mann-Whitney 
U test, or χ² test.
We used multivariable linear regression analysis to 
assess the relationship between PWV and exposure to 
adiposity. In the primary complete-case analysis (ie, the 
core model), we included the following covariates: sex, 
socioeconomic status, low-density lipoprotein (LDL) 
cholesterol, smoking, systolic blood pressure, C-reactive 
protein, birthweight, and BMI Z score at 17 years. Total 
fat mass was adjusted for height where applicable. 
Subsequently, we did a secondary analysis (ie, the 
expanded multivariable model) that controlled for the 
following additional confounders or mediators: 
accelerometer data for physical activity at age 15 years, 
parental and participant’s smoking, and puberty status 
(Tanner stage; appendix). In this analysis, we replaced all 
missing data by multiple imputation using the Markov 
chain Monte Carlo method (appendix). We used observed 
and imputed data on exposure cardiometabolic variables 
to derive combined categories of metabolic health 
(metabolically healthy vs metabolically unhealthy) and 
total FMI status on the two occasions with maximum 
time difference (ages 9 and 17 years). A test for linear 
trend (ie, levels of PWV across ordinal groups) was done 
across prespecified categories of interest, based on 
specific combinations of baseline and changes in fat mass 
and metabolic status, after regression models. A positive 
test for trend suggests a linear association (increase or 
decrease) between the dependent variable (PWV) and the 
levels of the ordinal independent variable; in other words, 
the effect of combined fat exposure and metabolic 
derangements on PWV will linearly increase per 
transition from lower to higher category, irrespectively of 
which category a child is classified in. To assess the effect 
of longitudinal changes in adiposity indices through 
adolescence on arterial stiffness, we used latent class 
growth (LCG) mixture modelling analysis.14 Multiple 
measurements of total fat, trunk fat, lean mass, and total 
body mass were indexed for height changes (ie, height 
squared). The LCG models contained random intercept 
and slope variances to account for between-subject 
heterogeneity in longitudinal changes in obesity 
measurements while the linear, quadratic, and cubic 
specifications for the within-subject response of these 
variables as a function of increasing age were evaluated 
(appendix).
We used Stata, version 13.1, for statistical analysis and 
the lcmm package in RStudio (version 1.1.414) in LCG 
mixture modelling analysis. All tests were two sided. A 
priori, we planned to draw conclusions on the basis of 
effect estimates and their CIs, rather than statistical tests 
using an arbitrary p value cutoff. For example, given 
two effects with the same point estimate—one with 
narrow CIs, the other with wider CIs that could even 
include the null—we describe both as showing the same 
effect but note that one is more imprecisely estimated 
and should be treated with more caution until replicated 
in a larger sample.
Role of the funding source
The funders had no role in the design and conduct 
of the study; collection, management, analysis, and 
interpretation of data; and preparation, review, or 
approval of the manuscript. The corresponding author 
had full access to all of the data and the final responsibility 
to submit for publication.
Results
We included 3423 participants in this study, of whom 
1557 (45·5%) were male and 1866 (54·5%) were female 
(table 1). Of these participants, 3046 (89%) had DEXA and 
height measurements at ages 9 and 17 years. 1990 (65%) 
participants had normal FMI (ie, <75th percentile) in both 
periods, 294 (10%) initially had normal FMI but increased 
to high FMI at age 17 years, 288 (9%) had high FMI at age 
9 years but normal FMI at age 17 years, and 474 (16%) had 
consistently high FMI. The association between FMI 
status and cardiometabolic parameters at ages 9 and 
17 years is shown in table 2.
In the longitudinal analysis, participants with sufficient 
measurements were classified into high, middle, and low 
trajectories of total and trunk FMI created by LCG analysis 
according to longitudinal fat mass. Regarding total FMI, 
most of the 3417 children followed the middle trajectory 
(n=1544), while 560 participants followed the high 
trajectory and 1313 participants followed the low trajectory 
(appendix). Three trunk FMI groups were identified on 
3290 participants (appendix): participants with high 
truncal FMI throughout adolescence (n=569), the middle 
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trajectory (n=991), and low trajectory (n=1730). Finally, we 
identified two trajectories of fat-free mass index (low 
[n=1888] and high [n=1529]) and three trajectories of BMI 
changes (low [n=1222], middle [n=1522], and high [n=679]).
In cross-sectional analyses at age 17 years, total fat 
mass was positively associated with PWV and there was 
weak evidence of a positive association between trunk fat 
mass and PWV (table 3). These associations remained 
following adjustment for demographic, haemodynamic, 
and metabolic parameters (table 3). After multiple 
imputation, total fat mass was still independently 
positively associated to PWV (0·01 m/s per kg, 
95% CI 0·00–0·02; p=0·0056). Following cross-sectional 
analysis, only fat mass at ages 9, 11, and 17 years were 
independently associated with PWV (appendix) and the 
strength of association was highest for 9 years of age, 
suggesting that this might be an important age at which 
to test whether weight loss intervention could have a 
long-term beneficial effect on arterial stiffness (appendix).
Persistently high total FMI was associated with greater 
PWV at age 17 years (table 4; appendix). This association 
remained after multivariable adjustment. No interaction 
was found between sex and FMI on PWV at age 17 years 
(data not shown). After multiple imputation for missing 
values, the association between persistently high total 
FMI and greater PWV remained (0·10 m/s per kg/m², 
95% CI 0·03–0·18; p=0·0069). Similarly, persistently 
high trunk FMI was associated with greater PWV and 
retained its association after multivariable adjustment 
(table 4) and imputation (0·12 m/s per kg/m², 0·04–0·19, 
p=0·0017).
We found little evidence to support the association of 
high fat-free mass index and PWV at age 17 years 
compared to low fat-free mass index(data not shown).
Compared with participants who were metabolically 
healthy and had normal FMI, participants with 
persistently high FMI had elevated PWV (6·2 m/s 
[95% CI 5·9–6·4] for metabolically unhealthy participants 
and 6·0 m/s [5·9–6·0] for metabolically healthy 
participants), as did children who simultaneously 
increased their FMI from ages 9 to 17 years and were 
metabolically unhealthy (PWV 6·2 m/s, 95% CI 5·9–6·5; 
figure). Notably, participants who decreased their FMI to 
normal ranges from age 9 years to age 17 years had 
comparable PWV to those who had normal FMI 
throughout those ages irrespective of their metabolic 
status (5·8 m/s [5·7–5·9] for metabolically healthy 
participants and 5·9 m/s [5·6–6·1] for metabolically 
unhealthy participants). Participants who had normal 
FMI at both periods but were metabolically unhealthy 
Age 9 years Age 17 years p value for 
change*
Female (n=1866) Male (n=1557) p value Female (n=1866) Male (n=1557) p value
Weight, kg 38·0 (8·1) 37·3 (7·4) 0·0064 61·9 (11·6) 71·1 (11·9) <0·0001 <0·0001
Height, cm 140 (7) 140 (6) 0·81 166 (6) 179 (7) <0·0001 <0·0001
BMI, kg/m² 18·2 (2·9) 17·8 (2·7) 0·00037 22·6 (3·9) 22·2 (3·4) 0·0014 0·60
Waist-to-height ratio 0·44 (0·42–0·42) 0·44 (0·42–0·47) 0·51 0·45 (0·43–0·49) 0·43 (0·41–0·45) <0·0001 <0·0001
Total fat mass, kg 8·4 (5·9–11·7) 5·7 (4·0–8·9) <0·0001 19·2 (14·8–25·1) 10·2 (6·9–16·6) <0·0001 <0·0001
Trunk fat mass, kg 3·2 (2·1–4·9) 2·0 (1·4–3·4) <0·0001 8·2 (5·5–12·0) 8·5 (5·4–12·2) 0·53 <0·0001
Total fat mass indexed for 
squared height
0·41 (0·28–0·60) 0·30 (0·20–0·49) <0·0001 0·70 (0·55–0·90) 0·32 (0·21–0·52) <0·0001 0·0036
Trunk fat mass indexed 
for squared height
0·16 (0·10–0·24) 0·10 (0·07–0·19) <0·0001 0·30 (0·20–0·44) 0·27 (0·17–0·40) 0·012 0·53
Systolic blood pressure, 
mm Hg
104 (9) 103 (9) 0·0056 112 (8) 122 (9) <0·0001 <0·0001
Diastolic blood pressure, 
mm Hg
60 (8) 59 (8) <0·0001 65 (6) 63 (6) <0·0001 0·45
PWV carotid-femoral, m/s NA NA ·· 5·5 (0·6) 6·0 (0·7) <0·0001 ··
C-reactive protein, mg/L 0·26 (0·14–0·65) 0·15 (0·09–0·36) <0·0001 0·66 (0·32–1·55) 0·44 (0·26–0·92) <0·0001 0·056
Cholesterol, mmol/L 4·33 (0·62) 4·18 (0·65) <0·0001 3·94 (0·68) 3·56 (0·62) <0·0001 <0·0001
Triglycerides, mmol/L 1·04 (0·79–1·38) 0·97 (0·74–1·33) 0·0014 0·75 (0·6–0·98) 0·74 (0·59–0·95) 0·18 0·16
HDL, mmol/L 1·38 (0·30) 1·44 (0·31) <0·00001 1·36 (0·32) 1·19 (0·26) <0·0001 <0·0001
LDL, mmol/L 2·20 (0·57) 2·23 (0·58) <0·0001 2·20 (0·63) 2·43 (0·55) <0·0001 0·40
Insulin, pmol/L NA NA ·· 43·6 (32·5–58·3) 36·1 (26·4–51·0) <0·0001 ··
Glucose, mmol/L 4·9 (4·7–5·0) 4·9 (4·8–5·1) 0·017 4·9 (4·7–5·1) 5·1 (4·9–5·4) <0·0001 <0·0001
Adiponectin, × 10³ mg/mL 12·9 (9·4–16·9) 11·9 (8·9–15·5) 0·00020 NA NA ·· ··
Leptin, ng/mL 6·8 (4·2–11·5) 3·9 (2·6–7·3) <0·0001 NA NA ·· ··
Data are mean (SD) or median (IQR). p values represents differences between sex at the respective timepoints. BMI=body-mass index. PWV=pulse wave velocity. NA=not 
available. HDL=high-density lipoprotein. LDL=low-density lipoprotein. *p value for the difference in change from ages 9 years to 17 years between female and male participants. 
Table 1: Patient characteristics at ages 9 years and 17 years
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showed increased PWV compared to normal FMI and 
metabolic healthy group (PWV 5·7 m/s [5·7–5·8] and 
5·9 m/s [5·8–6·0] for metabolically healthy and 
unhealthy, respectively). Overall, the combination of high 
total fat mass and a metabolically unhealthy profile was 
linearly associated with increased PWV at age 17 years: a 
mean expected adjusted increase of 0·08 m/s (95% CI 
0·03–0·13) was shown in PWV per ascending category 
of combined fat mass exposure and metabolic health 
(p for linear trend=0·0034), with the lowest category 
comprising children who had normal fat mass and were 
metabolically healthy across adolescence and the highest 
comprising children who were obese and metabolically 
unhealthy at both ages 9 and 17 years (figure). After 
imputation, this effect did not change (mean increase 
0·03 m/s [0·01–0·04] per ascending category; p<0·0001).
BMI Z score correlated with total FMI at age 17 years 
(rs = 0·76; p<0·0001) but not at age 9 years (rs = −0·006; 
p=0·84). At age 17 years, 1090 (33%) of 3318 participants 
were misclassified in their adiposity status by BMI 
compared with total FMI (ie, participants were either 
considered to be normal weight by BMI but overweight 
or obese by total FMI or vice versa). Waist-to-height ratio 
was not associated with total or trunk FMI at any 
timepoint during adolescence. BMI and waist-to-height 
ratio were not related to arterial stiffness (table 3). High 
trajectory of BMI across adolescence was related to 
greater arterial stiffness but adjustment for cardio-
metabolic factors, including birthweight, attenuated the 
association with PWV (table 4; appendix).
Age 9 years Age 17 years p value for 
change*
Normal FMI (n=2359) High FMI (n=785) p value Normal FMI (n=2490) High FMI (n=828) p value
Sex
Female 1278 (54·2%) 425 (54·1%) ·· 1131 (45·4%) 376 (45·4%) ·· ··
Male 1081 (45·8%) 360 (45·9%) ·· 1359 (54·6%) 452 (54·6%) ·· ··
Weight, kg 35·5 (6·4) 44·3 (7·8) <0·0001 64 (11·6) 72·5 (13·1) <0·0001 <0·0001
Height, cm 141 (5) 152 (4) <0·0001 169 (8) 180 (8) <0·0001 0·81
BMI, kg/m² 17·7 (2·7) 19·0 (3·1) <0·0001 22·4 (3·7) 22·4 (3·7) 0·91 0·0029
Waist-to-height ratio 0·44 (0·42–0·47) 0·44 (0·42–0·48) 0·83 0·44 (0·42–0·48) 0·44 (0·41–0·47) 0·0050 0·026
Total fat mass, kg 5·9 (4·3–8·0) 14·0 (12·6–16·8) <0·0001 13·0 (8·6–17·3) 28·0 (24·8–34·1) <0·0001 <0·0001
Trunk fat mass, kg 2·1 (1·5–3·0) 6·0 (4·9–7·5) <0·0001 8·7 (5·7–12·5) 7·8 (4·7–10·8) 0·0096 <0·0001
Total fat mass indexed for squared 
height, kg/m²
0·29 (0·21–0·40) 0·72 (0·62–0·88) <0·0001 0·45 (0·27–0·61) 0·99 (0·86–1·19) <0·0001 <0·0001
Trunk fat mass indexed for squared 
height, kg/m²
0·10 (0·07–0·15) 0·31 (0·25–0·39) <0·0001 0·29 (0·19–0·44) 0·27 (0·16–0·37) 0·025 <0·0001
Systolic blood pressure, mm Hg 103 (9) 105 (9) <0·0001 116 (10) 118 (10) <0·0001 0·00020
Diastolic blood pressure, mm Hg 59 (8) 59 (8) 0·22 64 (6) 64 (6) 0·64 0·0067
PWV femoral, m/s NA NA ·· 5·7 (0·7) 5·9 (0·8) <0·0001 ··
C-reactive protein, mg/L 0·20 (0·11–0·53) 0·22 (0·11–0·49) 0·72 0·53 (0·29–1·3) 0·55 (0·27–1·20) 0·95 0·45
Cholesterol, mmol/L 4·29 (0·64) 4·17 (0·61) 0·00017 3·77 (0·67) 3·69 (0·70) 0·0073 0·72
Triglycerides, mmol/L 1·01 (0·78–1·35) 1·00 (0·75–1·39) 0·61 0·74 (0·60–0·96) 0·75 (0·60–0·97) 0·90 0·87
HDL, mmol/L 1·41 (0·31) 1·38 (0·29) 0·028 1·27 (0·31) 1·27 (0·30) 0·72 0·45
LDL, mmol/L 2·36 (0·58) 2·27 (0·55) 0·0019 2·12 (0·61) 2·05 (0·61) 0·019 0·90
Insulin, pmol/L NA NA ·· 39·8 (29·9–55·6) 39·7 (28·9–54·7) 0·59 ··
Glucose, mmol/L 4·9 (4·7–5·1) 4·9 (4·8–5·1) 0·65 5·0 (4·8–5·2) 5·0 (4·8–5·3) 0·80 0·19
Adiponectin, × 10³ mg/mL 12·0 (9·2–16·3) 12·0 (8·9–16·1) 0·30 NA NA ·· ··
Leptin, ng/mL 4·7 (3·0–8·8) 7·0 (4·2–13·3) <0·0001 NA NA ·· ··
Data are mean (SD) or median (IQR). Normal fat mass (≤75th percentile) and high fat mass (>75th percentile) groups for each time period were defined according to the distribution of total fat mass at ages 
9 years and 17 years after adjustment for height and sex. Fat measurements (total and trunk fat mass) are provided on the basis of unadjusted groups due to further height indexing. p values represent 
differences between high and normal fat mass at the respective timepoints. FMI=fat mass index. BMI=body-mass index. PWV=pulse wave velocity. HDL=high-density lipoprotein. LDL=low-density lipoprotein. 
NA=not available. *p value for the difference in change from ages 9 years to 17 years between participants with normal fat mass and high fat mass.
Table 2: Study population characteristics according to normal or high fat mass at ages 9 years and 17 years
Univariate analysis 
(n=3333)*
Multivariable adjusted analysis 
(n=1910)†
PWV coefficient, m/s 
(95% CI)
p value PWV coefficient, m/s 
(95% CI)
p value
Total fat mass, kg 0·004 (0·001 to 0·006) 0·0081 0·010 (0·002 to 0·016) 0·016
Trunk fat mass, kg 0·007 (−0·001 to 0·020) 0·073 0·010 (−0·010 to 0·024) 0·25
BMI, kg/m² 0·04 (−0·00 to 0·10) 0·23 ·· ··
Waist-to-height ratio 0·20 (−0·34 to 0·73) 0·48 ·· ··
 Multivariable adjusted analysis was done for significant univariate analyses. PWV=pulse wave velocity. LDL=low-density 
lipoprotein. BMI=body-mass index. *Adjusted for sex. †Adjusted for sex, systolic blood pressure, LDL, C-reactive protein, 
socioeconomic status, Z score of BMI, and birthweight (or fat when BMI was used as a dependent variable). 
Table 3: Cross-sectional associations of adiposity measures with PWV at age 17 years
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Discussion
In this study, we have shown that persistent high fat 
mass during adolescence is independently associated 
with increased arterial stiffness, one of the earliest 
markers of atherosclerotic disease. This adverse 
association was not apparent when routine clinical 
anthropometric measures of adiposity such as BMI or 
waist-to-height ratio were used and was amplified in the 
presence of a metabolically unhealthy phenotype. We 
also identified adolescence as an important period for 
preventive interventions because participants who lost 
fat during adolescence had similar arterial stiffness to 
those who had normal fat mass throughout. These 
findings suggest that targeted interventions to reduce 
obesity and its consequences in adolescence might 
translate into long-term vascular benefit.
Obesity in the young remains a highly complex medical 
problem in terms of cause. Several longitudinal studies 
have shown that obesity tracks from childhood to 
adulthood and increased weight gain in early childhood 
can predict obesity in adolescence and might help to 
identify individuals at risk.15 Although obesity has been 
associated with adverse cardiovascular outcomes in 
adulthood, its influence during the long preclinical phase 
of arterial disease remains less well defined. Adaptive 
vascular responses in peripheral arteries in relation to 
increased adiposity in childhood has previously been 
shown.5–7 Because evidence suggests that central arteries 
(ie, the aorta) might be more vulnerable to atherosclerosis, 
we chose to assess aortic stiffness as measured by PWV 
between carotid to femoral arterial segments16 rather 
than carotid to radial arterial segments, which reflect 
changes in a muscular artery (the brachial artery) that is 
not reflective of developing atherosclerosis. Studies have 
shown that PWV measurements are reproducible and 
that increased PWV can predict adverse outcome such 
as cardiovascular events and mortality in adults.16 
The present study has shown that increases in directly 
measured body fat, as assessed by DEXA during 
adolescence, appear to be associated with greater PWV in 
late adolescence. These findings contradict a previous 
study, which showed that increased adiposity is associated 
with reduced arterial stiffness in children and adolescents 
and that an adverse association is only apparent in later 
life.17 It is possible that the use of body fat percentage 
rather than absolute values of fat mass could account for 
this discrepancy.
The pattern of fat distribution, rather the quantity of fat 
mass, might also be important in determining cardio-
vascular risk, as excess fat in the central regions of the 
body rather than the gluteofemoral area has been more 
strongly associated with deleterious health outcomes.18 
In our study, although truncal fat was associated with 
increased arterial stiffness, only total fat was related to 
PWV in multivariable analysis. As total fat measured by 
DEXA provides information of both visceral and 
subcutaneous fat, this finding suggests that any type of 
fat might be important in determining vascular risk at 
this stage, whereas metabolic risk is more closely related 
to BMI and truncal fat mass.19 Previous studies have 
shown a strong correlation between truncal and visceral 
fat in adults;20 however, such a link is not clear in 
adolescence. Although waist circumference provides a 
reliable estimate of visceral adipose tissue in some 
studies,21 this finding is not supported in others.22 In our 
Univariate analysis 
(n=3417)*
Multivariable adjusted analysis 
(n=1940)†
PWV coefficient, m/s 
(95% CI)
p value PWV coefficient, m/s 
(95% CI)
p value
Total FMI (kg/m²)
Low trajectory −0·00 (−0·06 to 0·05) 0·95 0·02 (−0·06 to 0·09) 0·65
High trajectory 0·07 (0·01 to 0·14) 0·027 0·15 (0·05 to 0·24) 0·0044
Trunk FMI (kg/m²)
Low trajectory −0·03 (−0·08 to 0·02) 0·27 −0·03 (−0·10 to 0·04) 0·41
High trajectory 0·10 (0·03 to 0·17) 0·0041 0·15 (0·06 to 0·25) 0·0021
BMI trajectories (kg/m²)
Low trajectory 0·01 (−0·04 to 0·06) 0·59 −0·05 (−0·11 to 0·02) 0·18
High trajectory 0·09 (0·03 to 0·16) 0·0030 0·04 (−0·04 to 0·13) 0·34
In each case, the middle trajectory is the reference group. PWV=pulse wave velocity. LDL=low density lipoprotein. 
FMI=fat mass indexed to squared height. BMI=body-mass index. *Adjusted for sex. †Adjusted for sex, systolic blood 
pressure, LDL, C-reactive protein, socioeconomic status, Z-score of BMI at 17 years (except for models incorporating 
trajectories of BMI), and birthweight. 
Table 4: Associations of adiposity trajectories through adolescence with PWV
Figure: PWV per combinations of metabolic health and adiposity status at 9 and 17 years of age
Metabolically healthy includes all participants categorised as metabolically healthy at both 9 and 17 years of age, 
whereas metabolically unhealthy includes all participants categorised as metabolically unhealthy at either 9 or 
17 years of age. The reference category comprised children who had normal fat mass and were metabolically 
healthy across adolescence. p values for linear trend are derived from multivariable regression analysis for PWV at 
17 years adjusted for sex, height, socioeconomic status, systolic blood pressure, C-reactive protein, LDL, Z score of 
BMI, and birthweight. BMI=body-mass index. LDL=low-density lipoprotein. PWV=pulse wave velocity. *Significant 
difference (p<0·05) from the reference category.
5·6
5·8
6·0
6·2
6·4
6·6
Normal fat mass
PW
V 
(m
/s
)
Fat gain Fat loss High fat mass
Number of participants
Metabolically healthy
Metabolically unhealthy
2122
245
271
23
232
56
410
64
*
*
*
*
Metabolically healthy (both ages)
Metabolically unhealthy (either age)
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study, the association between waist-to-height ratio and 
DEXA-derived obesity measurements was weak for total 
and truncal fat, suggesting that the contribution of 
visceral fat might be less important at this age. It is also 
possible that the amount of visceral fat in this generally 
healthy cohort of young participants is small and 
therefore we were unable to show significant associations.
Adolescents affected by obesity are also at increased risk 
of developing other cardiovascular risk factors such as 
dyslipidaemia, hypertension, and insulin resistance—a 
combination commonly referred to as metabolic 
syndrome.13,23 Whether a constellation of these risk factors 
increases cardiovascular risk over and above adiposity in 
children and adolescents remains a matter of controversy. 
Some, but not all, studies have shown greater alterations 
of cardiovascular structure and function in children with 
the combination of obesity and metabolic syndrome 
compared with children without it.23 In the ALSPAC 
cohort, the presence of established metabolic syndrome 
as defined in adults is low, and we have used percentiles 
to separate the metabolically healthy from unhealthy 
participants, as previously used by others.13 We used a 
combination of three or more cardiovascular risk factors 
to define metabolic health and, consistent with previous 
reports, we showed that participants who had the 
persistent high fat mass and had a metabolically 
unhealthy phenotype had the highest arterial stiffness. 
These findings suggest that risk factor management is 
also important in reducing cardiovascular risk and 
complement previous reports showing that the number 
of cardiovascular events could be decreased by treatment 
of obesity-related risk factors such as hypertension and 
dyslipidaemia.24 In the current study, participants who 
had high fat mass but were yet to accrue metabolic 
abnormalities still showed elevated arterial stiffness, 
suggesting that even in the absence of additional risk 
factors, strategies to reduce fat mass could be beneficial. 
In the 1946 birth cohort, our group has previously shown 
that achieving weight loss at any point in life, even if not 
sustained, was beneficial for vascular health.25 Consistent 
with this and other observations, 26 we show in this study 
that reduction of fat mass in adolescence is beneficial 
because participants who normalised their FMI in 
adolescence had comparable arterial stiffness to those 
who had consistently normal FMI. The association of 
total fat mass with arterial stiffness was stronger at 9 years 
of age than the other time periods, which suggests that 
strategies to prevent obesity in this period could be 
beneficial for future cardiovascular health; however, this 
needs further study.
In addition to DEXA, we also measured other more 
commonly used adiposity indices and related them to fat 
mass and arterial stiffness. As previously described, the 
association between BMI and body fat is weak in children 
and strong association becomes more apparent only in 
adulthood.27 This probably reflects the inability of BMI to 
discriminate between fat and fat-free mass and to 
decipher physiological changes that alter their relative 
amounts during adolescence with growth and puberty. 
In adolescence, the differentiation between growth and 
increasing adiposity becomes more challenging, partly 
because of rapid changes in body composition in 
response to growth and sex hormones. In this cohort, 
BMI was not associated with arterial stiffness in the 
cross-sectional analyses but the relationship was 
apparent in the longitudinal analysis and was mostly 
explained by the presence of metabolic abnormalities. 
These results suggest that in adolescence, a more detailed 
phenotype such as DEXA-derived FMI might be needed 
when assessing a relationship between adiposity and 
certain markers of vascular disease. As a measure of 
combined risk from adiposity and metabolic health, BMI 
could still be considered a useful tool for risk stratification 
in the clinical setting.
Our study has a number of strengths and limitations. A 
variety of metabolic parameters were collected in 
childhood and adolescence, which allowed us to identify 
the combined effect of adiposity status and metabolic 
profile on arterial stiffness. However, the presence of 
unmeasured or residual confounders cannot be excluded. 
Indeed, several studies have shown strong associations 
between leptin, adiponectin, and cardiovascular disease.28 
In our study, adipocytokines were only measured in 
childhood; thus, we were unable to determine whether 
changes in adipocytokine levels and other unmeasured 
factors can account for the noted associations. In addition, 
the vast majority of our participants were of white British 
background, so extrapolation to other ethnic backgrounds 
is inappropriate. Non-fasting blood samples were collected 
in childhood and fasting blood samples were collected at 
17 years of age. Although lipid profile might not be affected 
by fasting state,29 some variability in the measurements 
for triglycerides and glucose, which might have led to 
misclassification of the metabolic profile of participants, 
cannot be excluded. However, we elected to use 
accelerometers at two timepoints to accurately assess 
fitness levels rather than relying on self-reported 
questionnaires, which should increase the accuracy of our 
results. Finally, as in all cohort studies, causal associations 
cannot be established. Despite these limitations, our serial 
assessment allowed us to determine the relationship 
between fat mass and that of metabolic parameters on 
arterial stiffness.
In conclusion, we have shown that persistent high fat 
mass from childhood was associated with an adverse 
effect on arterial stiffness at age 17 years and this effect 
was apparent in the presence or absence of metabolic 
abnormalities. Individuals who normalised their fat 
mass during adolescence had comparable PWV to those 
who had normal fat mass throughout. These findings 
suggest further interventional studies are needed to 
assess whether aggressive weight loss and metabolic 
control strategies during adolescence could provide long-
term vascular benefits.
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